Haolan Lu

2.1k total citations · 2 hit papers
33 papers, 1.6k citations indexed

About

Haolan Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Haolan Lu has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Haolan Lu's work include Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Peptidase Inhibition and Analysis (7 papers). Haolan Lu is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Peptidase Inhibition and Analysis (7 papers). Haolan Lu collaborates with scholars based in United States, China and Germany. Haolan Lu's co-authors include Thomas J. Lynch, Fabrice Barlési, Jean-Marie Cuillerot, Alexander Luft, Raju Titus Chacko, Martin Reck, Piotr Serwatowski, Igor Bondarenko, Martin Sebastian and Joel W. Neal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Endocrinology.

In The Last Decade

Haolan Lu

33 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2012 816 citations Thomas J. Lynch, Fabrice Barlési et al. Journal of Clinical Oncology profile →
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

2022 125 citations Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haolan Lu United States	16	1.2k	492	479	384	114	33	1.6k
Juan Martín-Liberal Spain	19	1.1k 0.9×	431 0.9×	415 0.9×	346 0.9×	58 0.5×	84	1.6k
Pallavi S. Mishra‐Kalyani United States	22	883 0.7×	560 1.1×	197 0.4×	332 0.9×	61 0.5×	49	1.5k
Jasmine I. Rizzo United States	8	1.1k 0.9×	239 0.5×	465 1.0×	382 1.0×	48 0.4×	18	1.3k
Ruggero Ridolfi Italy	25	1.9k 1.6×	408 0.8×	1.1k 2.4×	774 2.0×	73 0.6×	97	2.4k
Gisela Schwab United States	13	644 0.5×	352 0.7×	166 0.3×	361 0.9×	334 2.9×	23	1.3k
Bradley Curtis Carthon United States	20	922 0.8×	706 1.4×	321 0.7×	258 0.7×	135 1.2×	115	1.7k
Erika Rijavec Italy	24	1.1k 0.9×	707 1.4×	253 0.5×	489 1.3×	132 1.2×	93	1.7k
Geoffrey Kim United States	18	621 0.5×	354 0.7×	156 0.3×	205 0.5×	61 0.5×	29	1.0k
Débora De Melo Gagliato Brazil	14	953 0.8×	528 1.1×	281 0.6×	426 1.1×	127 1.1×	36	1.5k
Tien Hoang United States	22	1.8k 1.5×	1.4k 2.9×	276 0.6×	414 1.1×	118 1.0×	70	2.4k

Countries citing papers authored by Haolan Lu

Since Specialization

Citations

This map shows the geographic impact of Haolan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haolan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haolan Lu more than expected).

Fields of papers citing papers by Haolan Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haolan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haolan Lu. The network helps show where Haolan Lu may publish in the future.

Co-authorship network of co-authors of Haolan Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Haolan Lu. A scholar is included among the top collaborators of Haolan Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haolan Lu. Haolan Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yi, Yuxi Zhang, Jilan Chen, et al.. (2023). Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer. International Immunopharmacology. 123. 110686–110686. 7 indexed citations

Zhang, Yuxi, Yi Wang, Yanping Li, et al.. (2022). Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer. Biochemical Pharmacology. 198. 114941–114941. 27 indexed citations

Gào, Xīn, Howard A. Burris, Jacqueline Vuky, et al.. (2022). Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(6_suppl). 17–17. 125 indexed citations breakdown →

Hamilton, Erika, Anne F. Schott, Rita Nanda, et al.. (2022). ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.. Journal of Clinical Oncology. 40(16_suppl). TPS1120–TPS1120. 52 indexed citations

Li, Jian, Yanhong Deng, Weijie Zhang, et al.. (2021). Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. Journal of Hematology & Oncology. 14(1). 95–95. 92 indexed citations

Zhang, Yuxi, Yi Wang, Yanping Li, et al.. (2021). Dihydroartemisinin and Artesunate Inhibit Aerobic Glycolysis via Suppressing c-Myc Signaling in Non-Small Cell Lung Cancer. SSRN Electronic Journal. 4 indexed citations

Yin, Xianli, Yun Zhang, Yanhong Deng, et al.. (2020). Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.. Journal of Clinical Oncology. 38(15_suppl). e16585–e16585. 4 indexed citations

Shen, Lin, Jian Li, Yanhong Deng, et al.. (2020). Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.. Journal of Clinical Oncology. 38(15_suppl). 3021–3021. 4 indexed citations

Shimizu, Toshio, Takako Eguchi Nakajima, WenLian Xu, et al.. (2019). Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 2609–2609. 5 indexed citations

10.

Peters, Solange, Federico Cappuzzo, Leora Horn, et al.. (2017). OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. Journal of Thoracic Oncology. 12(1). S253–S253. 37 indexed citations

11.

Paz‐Ares, Luis, Julie R. Brahmer, Matthew D. Hellmann, et al.. (2017). CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. ii50–ii51. 9 indexed citations

12.

Deeken, John F., André Liem, David P. Hill, et al.. (2013). Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. Cancer Chemotherapy and Pharmacology. 71(6). 1473–1483. 14 indexed citations

13.

Guarino, Michael J., Charles Schneider, Julie R. Brahmer, et al.. (2009). Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies. The Oncologist. 14(2). 119–124. 18 indexed citations

14.

Trippett, Tanya, Cynthia E. Herzog, James A. Whitlock, et al.. (2009). Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium. Journal of Clinical Oncology. 27(30). 5102–5108. 38 indexed citations

15.

Patel, Taral, Luke Dreisbach, Michael McCleod, et al.. (2009). Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial. Journal of Clinical Oncology. 27(15_suppl). e19011–e19011. 2 indexed citations

16.

Ramalingam, Suresh S., et al.. (2008). Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study. Journal of Thoracic Oncology. 3(3). 258–264. 43 indexed citations

17.

Guarino, Michael J., Charles Schneider, Julie R. Brahmer, et al.. (2007). Dual inhibition of the epidermal growth factor receptor (EGFR) pathway with the combination of cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies. Molecular Cancer Therapeutics. 6. 2 indexed citations

18.

Lu, Haolan, Cavan Reilly, Sudipto Banerjee, & Bradley P. Carlin. (2007). Bayesian areal wombling via adjacency modeling. Environmental and Ecological Statistics. 14(4). 433–452. 49 indexed citations

19.

Lu, Haolan, James S. Hodges, & Bradley P. Carlin. (2007). Measuring the complexity of generalized linear hierarchical models. Canadian Journal of Statistics. 35(1). 69–87. 10 indexed citations

20.

Woodward, Terry L., Haolan Lu, & Sandra Z. Haslam. (2000). Laminin Inhibits Estrogen Action in Human Breast Cancer Cells¹. Endocrinology. 141(8). 2814–2821. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact